Immunovant Could Potentially Be An M&A Target, Writes Analyst

• Cantor Fitzgerald initiated coverage on Immunovant Inc (NASDAQ: IMVT) with an Overweight rating and a price target of $30.

• The company's pipeline includes batoclimab (IMVT-1401) and IMVT-1402, fully human, monoclonal antibodies targeting the neonatal fragment crystallizable receptor (FcRn).

• Batoclimab has demonstrated its potential to reduce immunoglobulin G (IgG) antibodies that cause inflammation, while IMVT-1402 has also demonstrated profound IgG antibody reduction in animal studies.

• Related: Immunovant's New Candidate Provides Some Strategic Flexibility & Clarity, Analysts Say.

• Expected positive data readouts beginning in 2023+ from batoclimab and IMVT-1402 trials could drive shares higher, potentially narrowing the valuation gap between IMVT's market cap and its competitors, such as Argenyx SE (NASDAQ: ARGX).

• Additionally, IMVT could attract potential strategic interest, as evidenced by Johnson & Johnson's (NYSE: JNJ) 2020 acquisition of anti-FcRn company Momenta Pharma for $6.5 billion.

• IMVT's parent company Roivant Sciences Ltd (NASDAQ: ROIV), indicated in its 3Q22 earnings call that it would take a commercial view of any potential M&A inquiry relating to the company.

• Price Action: IMVT shares are down 3.79% at $17.89 on the last check Wednesday.

Latest Ratings for IMVT

Date	Firm	Action	From	To
Dec 2021	Wells Fargo	Initiates Coverage On		Equal-Weight
Nov 2021	HC Wainwright & Co.	Maintains		Buy
Aug 2021	Baird	Downgrades	Outperform	Neutral

View More Analyst Ratings for IMVT

View the Latest Analyst Ratings

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Immunovant Could Potentially Be An M&A Target, Writes Analyst originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.